acquiredZebra Medical Vision

Zebra Medical Vision reads X-rays and CTs with AI triage tools for radiologists

An occupier-company imaging-AI startup that built FDA-cleared algorithms flagging pneumothorax, brain bleeds, and bone disease on scans, then sold to fellow occupier-company Nanox and became Nanox AI.

شركة احتلال ناشئة في فلسطين المحتلة طوّرت ذكاءً اصطناعياً لقراءة الأشعة السينية والمقطعية قبل أن تستحوذ عليها شركة نانوكس.

Next →
  1. The Bottleneck

    What was broken?

    Radiology departments drown in scans: chest X-rays and head CTs pile up faster than radiologists can read them, so critical findings like collapsed lungs or brain bleeds wait in the queue.

  2. The Move

    Why it worked

    Trained deep-learning models on large imaging datasets and packaged them as an all-in-one triage bundle (AI1) that plugs into existing PACS/worklist systems — clearing FDA 510(k)s finding by finding instead of betting on one flagship algorithm.

  3. The Trap

    Battle scars

    A pioneer that struggled to convert technology into sales; thin per-scan economics, long hospital procurement cycles, and dependence on partners' distribution — ending in a cut-price exit far below early hype.

The problem

Scans pile up faster than radiologists can read them. A chest X-ray showing a collapsed lung or a head CT with a bleed can sit in the queue for hours — not because the diagnosis is hard, but because nobody has looked yet.

How it works

An occupier-company founded in 2014 in Shefayim (Occupied Palestine), backed by US venture capital — not a Palestinian company. Founded by Eyal Toledano, Eyal Gura (CEO), and Elad Benjamin, Zebra Medical Vision trained deep-learning models on large imaging datasets and sold them as the AI1 all-in-one bundle that plugs into hospitals’ existing PACS and worklist systems. HealthPNX, its FDA 510(k)-cleared pneumothorax alert, was described as the world’s first AI chest X-ray triage product at clearance in May 2019, alongside a brain-bleed CT alert and bone-health tools.

Pain points

Radiologist shortages and burnout, acute findings buried in first-in-first-out queues, and small hospitals lacking subspecialists to catch subtle positives.

Business model

Subscription software for imaging networks: one AI1 bundle covering the whole algorithm library, distributed direct and through PACS/teleradiology partners, priced on volume rather than per-diagnosis risk.

Challenges

Being first did not mean selling first: the company burned through $50M+ while hospital sales cycles dragged, per-scan pricing stayed thin, and distribution depended on partners. The 2021 exit — up to $200M announced, around $110M in stock at closing — priced a pioneer as a distressed asset.

Funding

  • Raised: $50M+ by May 2019 from Khosla Ventures, Marc Benioff, Intermountain, OurCrowd, aMoon, Nvidia, J&J, and Dolby Ventures.
  • Valuation: ~$110M all-stock value at closing (Medical Device Network, Nov 2021).

Latest — Nov 2021

On 9 November 2021 Medical Device Network reported Nanox had completed its acquisition of Zebra Medical Vision — now operating as Nanox AI with seven FDA-cleared and ten CE-marked solutions — with Nanox CEO Ran Poliakine calling the closing “another step on our path to democratising the delivery of healthcare.”

Similar sparks

⚡️ PRE-SEEDVal: $200K

Syria · 2026-09-26

Doctorbook connects Syrian patients to doctors with AI-explained results

A medical booking platform where Syrian patients find trusted doctors, book appointments, and get AI-simplified explanations of lab and radiology reports with specialist guidance.

بالعربي

منصة طبية سورية تربط المرضى بالأطباء للحجز الإلكتروني وتشرح نتائج التحاليل والأشعة بالذكاء الاصطناعي بلغة مبسطة.

  • healthtech
  • #syria
⚡️ SERIES C+$125M+ cumulative

Japan · 2025-06-26

Ubie guides you to the right doctor before you book one

Answer a few questions on Ubie's AI symptom checker and get a medically-vetted read on what might be wrong and where to go next — free for patients, sold as intake software to hospitals.

بالعربي

أجب عن أسئلة قليلة في أداة يوبي الذكية لفحص الأعراض واحصل على توجيه طبي موثوق نحو التخصص المناسب — مجانًا للمرضى وبرنامج مدفوع للمستشفيات.

  • healthtech
  • #japan
⚡️ PUBLICVal: ≈$320M market cap at Jul 2022 Kosdaq IPO

South Korea · 2024-07-09

Lunit reads chest X-rays and mammograms with AI to catch cancer earlier

Lunit's FDA-cleared INSIGHT software flags tumors and critical findings in chest X-rays, mammograms, and tissue slides, giving radiologists a second reader that works in seconds.

بالعربي

تطوّر لونت برمجيات ذكاء اصطناعي حاصلة على ترخيص إدارة الغذاء والدواء تحلّل صور الصدر والماموغرام وشرائح الأنسجة لاكتشاف السرطان مبكرًا ومساعدة أطباء الأشعة على التشخيص.

  • healthtech
  • #south-korea
⚡️Spark playbook copied! Go build.